Table 2.
Revised categories and weights after inclusion of additional joint involvement category*
| Criterion and category | Score |
|---|---|
| Joint involvement (pattern and distribution) | |
| 1 medium-large joint | 0.0 |
| Asymmetric medium-large joints (at least 2 joints) | 10.1 |
| Symmetric medium-large joints (at least 2 joints) | 16.0 |
| 1–3 small joints (hands/feet or wrists) | 21.0 |
| ≥4 asymmetric small joints (hands/feet or wrists) | 27.7 |
| 4–10 symmetric small joints (hands/feet or wrists) | 29.4 |
| >10 joints including hands/feet or wrists | 50.5 |
| Serology (ACPA or RF) | |
| RF negative and ACPA negative | 0.0 |
| Low-positive (RF positive and/or ACPA positive) | 21.8 |
| High-positive (RF positive and/or ACPA positive) | 33.6 |
| Acute-phase reactants (CRP or ESR) | |
| Normal | 0.0 |
| Abnormal | 5.9 |
| Duration of synovitis | |
| <4 weeks | 0.0 |
| 4–8 weeks | 8.4 |
| >8 weeks | 10.1 |
Scores from each criterion are summed to derive the total score, which represents the probability of developing rheumatoid arthritis (RA).
ACPA = anti–cyclic citrullinated protein; RF = rheumatoid factor; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate.